Longitudinal retinal layer changes in preclinical Alzheimer's disease.

Autor: van de Kreeke JA; Ophthalmology Dept., Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Nguyen HT; Ophthalmology Dept., Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Konijnenberg E; Alzheimer Center, Neuroscience Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Tomassen J; Alzheimer Center, Neuroscience Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., den Braber A; Alzheimer Center, Neuroscience Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.; Dept. of Biological Psychology, VU University Amsterdam, Amsterdam, The Netherlands., Ten Kate M; Alzheimer Center, Neuroscience Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Yaqub M; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., van Berckel B; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Lammertsma AA; Department of Radiology and Nuclear Medicine, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Boomsma DI; Dept. of Biological Psychology, VU University Amsterdam, Amsterdam, The Netherlands., Tan HS; Ophthalmology Dept., Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Visser PJ; Alzheimer Center, Neuroscience Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Verbraak FD; Ophthalmology Dept., Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Acta ophthalmologica [Acta Ophthalmol] 2021 Aug; Vol. 99 (5), pp. 538-544. Date of Electronic Publication: 2020 Oct 18.
DOI: 10.1111/aos.14640
Abstrakt: Purpose: Several studies found reduced retinal thickness on optical coherence tomography (OCT) in Alzheimer's disease (AD), even in preclinical stages, labelling this technique of interest as biomarker. In this study, we examine retinal thickness changes in preclinical AD, as defined by cognitively normal individuals with amyloid-beta (Aβ) on positron emission tomography (PET).
Methods: For this monocentre study, 145 cognitively healthy monozygotic twins aged ≥ 60 were included from the Netherlands Twin Register taking part in the EMIF-AD PreclinAD study. At baseline, participants underwent [ 18 F] flutemetamol PET that was visually rated for cortical Aβ. Binding potential was calculated as continuous measure for Aβ. Optical coherence tomography (OCT) was performed at baseline and after 22 months to assess changes in total and individual inner retinal layer thickness in the macular region (ETDRS circles) and peripapillary retinal nerve fibre layer thickness. Differences in rate of change between amyloid-beta positive and negative individuals and associations between binding potential and change in retinal thickness were evaluated.
Results: Sixteen participants (11%) were positive for Aβ. Change in retinal thickness did not differ in any region between Aβ+ and Aβ- individuals. A positive association between binding potential and change in inner plexiform layer thickness was observed in the inner macular ring (beta = 1.708, CI = 0.575 to 2.841, p = 0.003).
Conclusion: Aβ+ individuals did not differ in rate of change of any retinal layer compared to controls, but higher binding potential at baseline was associated with less IPL thinning over time. Optical coherence tomography (OCT) as a longitudinal screening tool for preclinical AD seems limited, but IPL changes offer leads for further research.
(© 2020 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.)
Databáze: MEDLINE
Externí odkaz: